A Phase 1 interventional study of CSTI-500 in Prader-Willi Syndrome, sponsored by ConSynance Therapeutics. Completed at 1 site in United States. Open to participants aged 13 Years to 50 Years. Per ClinicalTrials.gov, last updated 2023-08-09.
Sponsored by ConSynance Therapeutics · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Prader-Willi Syndrome with a site in United States — 9 open to participants now, 14 under way, 3 of them phase 3. Prader-Willi Syndrome · United States.
Among the 69 studies in Prader-Willi Syndrome with a site in United States, this one is the 43rd largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2022, is one of 3 in phase 1, and was the 48th registered.
144 studies on the registry are indexed under Prader-Willi Syndrome; 23 are open to participants now.
Browse Prader-Willi Syndrome studies →9 of the 69 studies in Prader-Willi Syndrome with a site in United States are open now. Recruiting first, the newest first:
Children's Mercy Hospital Kansas City · Sites in United States
Ages 13–17
ConSynance Therapeutics · Sites in United States
Ages 13–50
Grace Kim · Sites in United States
Ages 18–26
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+ · Healthy volunteers
Harmony Biosciences Management, Inc. · Sites in United States, Australia, Belgium and 10 more countries
Ages 6+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 16 Prader-Willi Syndrome studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.
This study: 13 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 23 · Phase 3 16 · Phase 4 3
First in 1999; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 30 across 99 interventional studies indexed under Prader-Willi Syndrome.
Median enrollment 23 across the 58 interventional studies, 200 across the 11 observational. Of the 51 that completed or were terminated, 21 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 69 have an industry lead sponsor. The 10 most frequent:
ConSynance Therapeutics is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
ConSynance Therapeutics has 2 studies filed under Prader-Willi Syndrome — fewer than ten, so there is no comparison to draw.
7 of the studies in Prader-Willi Syndrome with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06366464Phase 3Harmony Biosciences Management, Inc.A Study of Pitolisant in Patients With Prader-Willi Syndrome | 2027-04 |
| NCT06144645Phase 3Foundation for Prader-Willi ResearchA Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS | 2027-04-01 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT06239116Rhythm Pharmaceuticals, Inc.A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment | 2027-05-07 |
| NCT07348601ConSynance TherapeuticsA Study of CSTI-500 in Patients With Prader-Willi Syndrome | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 69 studies in Prader-Willi Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this Phase 1 study is to evaluate the pharmacokinetics (PK) and safety of a single dose of CSTI-500 10 mg in subjects with Prader-Willi syndrome (PWS) between 13 and 50 years of age with a genetically confirmed diagnosis of PWS.
This is an open-label, single center, Phase 1 study to evaluate the PK and safety of a 10 mg single oral dose of CSTI-500, a triple monoamine reuptake inhibitor (TRI), in patients with genetically confirmed PWS. The study will consist of a Screening Period of up to 1-3 days prior to the Baseline Visit (Visit 2). In addition to the Screening Visit (Visit 1), eligible subjects will attend five in-clinic site visits for PK blood draws and safety assessments over a 6-day period. At Visit 2 all subjects will receive one single oral dose of CSTI-500 10 mg. Approximately 14 patients aged 13 to 50 years who meet all eligibility criteria will receive one single dose of CSTI-500.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All eligible subjects will be administered a single oral dose of CSTI-500 10 mg at Visit 2
Drug: CSTI-500
Single 10 mg capsule
Also known as: AMR-001181
Maximum Observed Plasma Concentration (Cmax)
Maximum observed plasma concentration following drug administration determined directly from the concentration-time profile.
Time frame: Pre-dose to 1, 2, 4, 8, 12, 24, 48, 72, and 144 hours post-dose
AUC0-72
Area under the plasma-drug concentration-time curve from pre-dose (time 0) to 72 hours after drug administration
Time frame: Pre-dose to 1, 2, 4, 8, 12, 24, 48, and 72 hours post-dose
AUC0-inf
Area under the plasma-drug concentration-time curve from pre-dose (time 0) extrapolated to infinite time
Time frame: Pre-dose to 1, 2, 4, 8, 12, 24, 48, 72, and 144 hours post-dose
CSTI-500 plasma concentration
Time frame: 1 hour post-dose
CSTI-500 plasma concentration
Time frame: 2 hour post-dose
CSTI-500 plasma concentration
Time frame: 4 hour post-dose
CSTI-500 plasma concentration
Time frame: 8 hour post-dose
CSTI-500 plasma concentration
Time frame: 12 hour post-dose
CSTI-500 plasma concentration
Time frame: 24 hour post-dose
CSTI-500 plasma concentration
Time frame: 48 hour post-dose
CSTI-500 plasma concentration
Time frame: 72 hour post-dose
CSTI-500 plasma concentration
Time frame: 144 hour post-dose
Incidence of treatment-emergent adverse events (TEAEs)
Number of participants with TEAEs, defined as an adverse event (AE) that is new or worsened in severity after the dose of study drug. AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and will be summarized by system organ class, preferred term, and treatment.
Time frame: From pre-dose to 15 days post-dose
Incidence of clinically significant findings in physical examinations
Time frame: Screening to 12, 24, 48, 72, and 144 hours post-dose
Incidence of clinically significant findings in vital signs
Participants will be assessed for any clinically significant changes in vital parameters (blood pressure, heart rate in supine and standing position, respiratory rate, and body temperature). This also includes evaluation of postural orthostatic tachycardic syndrome.
Time frame: Screening and pre-dose to 1, 2, 4, 8, 12, 24, 48, 72, and 144 hours post-dose
Incidence of clinically significant findings in laboratory values
Laboratory evaluations include hematology, thyroid function, and chemistry blood and urine laboratory tests.
Time frame: Screening to 24, 48, 72, and 144 hours post-dose
Incidence of clinically significant findings in 12-lead electrocardiograms (ECGs)
Time frame: Screening and pre-dose to 2, 4, 8, 12, 24, 48, 72, and 144 hours post-dose
Comparison of CSTI-500 Cmax values obtained from venous blood draws with values obtained from finger prick samples in PWS subjects
Time frame: Pre-dose to 1, 2, 4, 8, 12, 24, 48, 72, and 144 hours post-dose
Comparison of CSTI-500 AUC0-72 values obtained from venous blood draws with values obtained from finger prick samples in PWS subjects
Time frame: Pre-dose to 1, 2, 4, 8, 12, 24, 48, and 72 hours post-dose
Comparison of CSTI-500 AUC0-inf values obtained from venous blood draws with values obtained from finger prick samples in PWS subjects
Time frame: Pre-dose to 1, 2, 4, 8, 12, 24, 48, 72, and 144 hours post-dose
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2022 to primary completion in Feb 2023, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ConSynance Therapeutics